Other Events ·
Adial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, indicating it no longer satisfies the minimum…
ADILAzora Therapeutics, Inc. (DE)
Adial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, indicating it no longer satisfies the minimum stockholders' equity requirement of $2.5 million for continued listing under Rule 5550(b)(1). The company also lacks alternative quantitative standards regarding market value or net income. Adial has until October 2, 2026, to submit a compliance plan and may seek an extension of up to 180 days if the plan is accepted. The firm anticipates regaining compliance by converting its Series A Non-Voting Convertible Preferred Stock upon shareholder approval at the 2026 Annual Meeting. Adial Pharmaceuticals operates in the biopharmaceutical industry, developing treatments for central nervous system disorders.